What is claimed:

1. Use of a therapeutically effective amount of an LTA4H inhibitory agent that inhibits LTA4H aminopeptidase and epoxide hydrolase activity in the manufacture of a medicament for improving cognitive function in a subject diagnosed with an aging-associated cognitive impairment caused by neuroinflammation.

2. The use according to claim 1 wherein the aging-associated cognitive impairment caused by neuroinflammation is caused by a disease selected from the group consisting of Alzheimer's Disease, mild cognitive impairment, Parkinson's Disease, Parkinsonism, Frontotemporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, multiple sclerosis, dementia, dementia with Lewy bodies, and progressive supranuclear palsy.

3. The use according to claim 1 wherein the LTA4H inhibitory agent is a small organic molecule antagonist to LTA4H.

4. The use according to claim 1 wherein the LTA4H inhibitory agent is an antibody to LTA4H.

5. The use according to any of the preceding claims wherein the subject is a mammal.

6. The use according to claim 5 wherein the mammal is a human.

7. Use of a kit comprising an LTA4H inhibitory agent that inhibits LTA4H aminopeptidase and epoxide hydrolase activity in the manufacture of a medicament for improving cognitive impairment caused by neuroinflammation in a subject diagnosed with an-aging-associated cognitive disease.

8. The use according to claim 7 wherein the LTA4H inhibitory agent is a small organic molecule antagonist to LTA4H.

9. The use according to claim 7 wherein the LTA4H inhibitory agent is an antibody to LTA4H.